SCHEMBL12820641

SCHEMBL12820641

Cc1ccc(CSc2nc3c(=O)[nH]c(N)nc3[nH]2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ SCN9A Q15858 1/20 0.57
▸ NPC1 O15118 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ HPGD P15428 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ MMP13 P45452 1/20 0.50
▸ GAA P10253 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ RECQL P46063 1/20 0.46
▸ TNF P01375 1/20 0.46
▸ PLA2G1B P04054 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ NOD2 Q9HC29 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12820639 0.87 MAOB (0.52) NPC1ALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL12820638 0.87 SCN9A (0.56) SCN9ANPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL12820932 0.84 TP53 (0.54) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL12368142 0.80 TYMS (0.47) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL12820579 0.75 HTT (0.46) MEN1KMT2ASCN9AALDH1A1GAA
SCHEMBL12958935 0.74 XDH (0.50) MEN1KMT2ASCN9AALDH1A1RAB9A
SCHEMBL10007309 0.73 KDM4E (0.49) ALDH1A1MAPTLMNA
SCHEMBL12820629 0.72 KDM4E (0.42) ALDH1A1LMNA
SCHEMBL12820642 0.72 HSD17B10 (0.43) ALDH1A1RAB9ASMN1; SMN2MAPTRECQL
SCHEMBL12820575 0.72 MEN1 (0.45) MEN1KMT2AALDH1A1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120252791-A1 Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain CHILDREN'S MEDICAL CENTER CORPORATION 2012-10-04 — — US disclosed
US-20120252791-A1 Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain CHILDREN'S MEDICAL CENTER CORPORATION 2012-10-04 — — US disclosed
WO-2011035009-A1 HETEROCYCLIC GTP CYCLOHYDROLASE 1 INHIBITORS FOR THE TREATMENT OF PAIN HERCULES TECHNOLOGY MANAGEMENT CO V, INC. (US) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252791-A1 Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain GGH, GGPS1, GGT1 MEN1 4594/4885KMT2A 3807/4885SCN9A 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback